Earnings & Reporting

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

Radisson Hotel Group and SMHCC ink a deal for three new hotels, a strategic move to dominate the MICE market and capitalize on the Philippines' resurgence.

Fairholme's year-end dividends are more than just income. We dissect the funds' high-risk, non-diversified strategy and what it means for investors.

TPG RE Finance Trust declared a steady $0.24 dividend. We analyze if this signals portfolio resilience or a strategic play in a volatile market.

Valmet’s oversubscribed €375M Schuldschein loan isn't just a funding win. It's a strategic pivot showcasing the rising power of private debt markets.

A new partnership combines 3D depth with panoramic visuals, creating an unparalleled movie experience. But is it enough to win the premium cinema war?

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

New journalism awards tackle AI's risks and Indigenous health gaps, revealing how media innovation aims to build a healthier, more equitable Canada.

Nusano won a "Best Company" award, but the real story is how its culture is a strategic asset powering its mission to disrupt the critical isotope market.

KBRA rates a $328M mortgage trust with significant 'non-prime' loans, signaling a boom in a market segment that balances risk with investor demand.

With a new CEO, Menagerie Cellars is doubling down on its blend of luxury wine and conservation. Can this purpose-driven model scale in a tough market?

Lion Group's $8M Bitcoin purchase highlights a growing corporate trend, but a plunging stock price reveals the immense risks of digital asset treasuries.

A new inflation metric from Numerator does more than track prices; it signals a new era where private firms provide strategic economic intelligence.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

Beyond its first-ever dividend, Covalon's true story is one of clinical innovation driving record sales, navigating market shifts, and funding global growth.

Target's holiday push is more than a sale; it's a high-stakes play using AI, exclusive drops, and logistics to win the final days of retail's biggest battle.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

Shareholders approve Emeren's $102M deal to go private, a maneuver to accelerate growth in the booming solar and battery storage markets. What's next?